Cervical Cautery (Cervical Erosion Treatment) in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES:

• Women with symptomatic cervical ectropion confirmed on speculum examination and colposcopy, presenting with one or more of: profuse mucopurulent or clear discharge refractory to antibiotic therapy, recurrent post-coital bleeding (after malignancy excluded), chronic pelvic discomfort attributed to cervical inflammation, or repeated cervicitis episodes

• Women with an ectropion measuring >1 cm in diameter that has not responded to conservative management or treatment of underlying infection

• Women who have completed their family or who have been counselled on fertility implications of the chosen technique

• Women with a negative or low-grade (CIN 1) cervical biopsy result who wish to avoid ongoing surveillance anxiety

• REQUIRED PRE-PROCEDURE DIAGNOSTICS:

• Liquid-based cytology (LBC) cervical smear — must be within 12 months (or performed at initial consultation)

• High-risk HPV DNA testing (HPV 16, 18, and other high-risk genotypes) — co-testing preferred

• Colposcopy with acetic acid and Lugol's iodine application, including directed punch biopsy of any abnormal-appearing areas

• Endocervical swabs: Chlamydia trachomatis (NAAT), Neisseria gonorrhoeae (NAAT), bacterial vaginosis screen, and candida

• Transvaginal ultrasound (TVUS) to exclude concurrent uterine or adnexal pathology

• Full blood count (FBC), coagulation profile (PT/APTT/INR) if electrosurgical technique planned

• Pregnancy test (urine or serum beta-hCG) — pregnancy is an absolute contraindication to ablative cautery

• STI screen including HIV, Hepatitis B surface antigen where clinically indicated

• RELATIVE CONTRAINDICATIONS:

• Active cervicitis or unresolved pelvic inflammatory disease (PID) — treat infection first, defer procedure by minimum 6–8 weeks

• Current pregnancy (all ablative methods are contraindicated; ectropion in pregnancy is managed conservatively)

• Known or suspected high-grade CIN (CIN 2/3), AIS, or invasive cervical cancer — requires excisional treatment (LLETZ/LEEP/cone biopsy) or oncological referral, not simple ablation

• Unresolved coagulation disorder not optimised pre-operatively

• Immunosuppression (e.g., post-transplant, active autoimmune therapy) — requires specialist risk–benefit discussion

• Patient preference against the procedure after full informed consent discussion

TREATMENT APPROACHES FOR CERVICAL ECTROPION:

1. SILVER NITRATE CHEMICAL CAUTERY

The most conservative office-based technique. A silver nitrate applicator stick (75% concentration) is applied directly to the ectropion under direct vision without local anaesthesia. The coagulative chemical precipitates surface proteins, causing superficial tissue necrosis and stimulating squamous metaplasia. Best reserved for small (<1 cm), mildly symptomatic ectropions. Discomfort is minimal; a brown-black eschar forms and separates over 7–14 days. Single-session efficacy is approximately 60–70%; repeat applications may be needed. Does not generate a histological specimen.

2. CRYOTHERAPY (CRYOCAUTERY)

A cryoprobe cooled by liquid nitrogen or nitrous oxide (−80°C to −196°C) is applied to the ectropion for two freeze–thaw–freeze cycles of 3 minutes each. Ice-crystal formation destroys the columnar epithelium to a depth of 3–5 mm. Effective for ectropions up to 3 cm with no endocervical extension. A significant watery vaginal discharge lasting 3–4 weeks post-procedure is expected as the necrotic tissue sloughs. Efficacy: 80–90% for symptom resolution. No specimen generated; therefore HPV/CIN status must be confirmed negative before use. Still widely used in lower-resource settings and NABH-accredited district hospitals in India.

3. COLD COAGULATION (SEMM COAGULATOR)

Despite its name, 'cold coagulation' uses a Teflon probe heated to 100–120°C applied for 20–30 seconds per site. The technique is office-based, requires no general anaesthesia, produces less vapour/smoke than diathermy, and achieves tissue destruction to 4–6 mm depth. Multiple overlapping applications cover the entire transformation zone. Clinically preferred over cryotherapy in the UK (RCOG-endorsed) for outpatient ablation due to superior depth control and reduced discharge duration. Success rate 85–95%.

4. DIATHERMY / RADIOFREQUENCY ELECTROCAUTERY

Monopolar or bipolar radiofrequency (RF) energy (typically 3.8–4 MHz devices such as Ellman Surgitron or Medtronic Valleylab) is delivered via a ball or loop electrode. Thermal coagulation destroys tissue to a controlled depth of 3–8 mm. RF diathermy is performed under local anaesthetic (intracervical block with 1% lignocaine ± vasopressin). It is rapid, precise, and effective for larger or irregularly shaped ectropions. Produces smoke plume requiring evacuation. Success rates 88–95%.

5. LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE (LLETZ / LEEP)

The gold-standard excisional technique when histological confirmation of the transformation zone is required, or when colposcopic findings are borderline/equivocal. A thin wire loop (15–25 mm) energised with blended cutting/coagulation current excises the entire transformation zone as a single specimen, submitted for histopathological analysis. Performed under local anaesthetic (intracervical block). LLETZ simultaneously treats the ectropion and provides definitive tissue diagnosis. Depth of excision 7–10 mm for type 1–2 transformation zones. Mild bleeding risk (haemostasis achieved with ball diathermy); very rare risk (<1%) of cervical stenosis. Preferred technique in JCI/NABH centres for women with any colposcopic uncertainty.

6. LASER VAPORISATION (CO₂ LASER)

CO₂ laser (10,600 nm wavelength) vaporises the transformation zone with submillimetre precision under colposcopic guidance. Permits variable depth (2–7 mm) with minimal lateral thermal damage (~0.1 mm). Extremely low bleeding risk; superior healing time. Available at premium JCI-accredited tertiary centres in India (AIIMS, Tata Memorial, Apollo, Fortis) and in the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). Success rates 90–97%. Higher equipment cost makes it less widely available but offers the best outcomes for large or complex ectropions.

TECHNOLOGY COMPARISON SUMMARY:

• Office-based, no anaesthesia: Silver nitrate, cryotherapy

• Office-based, local anaesthesia: Cold coagulation, RF diathermy, LLETZ

• Theatre-based, local or general anaesthesia: LLETZ (large lesions), CO₂ laser

• Provides histological specimen: LLETZ only (among ablative options)

• Highest precision/lowest collateral damage: CO₂ laser > RF diathermy > cold coagulation

PRE-PROCEDURE PHASE (2–4 weeks before travel or at receiving centre):

• Step 1 — Remote Consultation: GAF Healthcare co-ordinates a telemedicine session with the receiving gynaecologist. The patient uploads recent smear results, HPV test, and any previous colposcopy reports. Medical history, menstrual cycle, contraception, and STI history are reviewed.

• Step 2 — Pre-procedure Diagnostics (at destination if not done locally): Liquid-based cytology, HPV DNA testing, colposcopy, directed biopsy (results within 48–72 hours at accredited labs), TVUS, swabs, blood tests, pregnancy test. The procedure is not booked until biopsy results confirm absence of high-grade CIN or malignancy.

• Step 3 — Scheduling: Procedure is ideally scheduled in the first half of the menstrual cycle (days 5–14) to avoid the luteal phase and reduce bleeding risk. Patient is advised to avoid intercourse and intravaginal products for 48 hours prior.

PROCEDURE DAY:

• Step 4 — Admission: Day-case admission. No general anaesthesia required for the majority of techniques (silver nitrate, cryotherapy, cold coagulation, RF diathermy, LLETZ under local block). The patient changes into a gown; a cannula is sited if IV sedation is offered for anxious patients.

• Step 5 — The Procedure: The patient is placed in the dorsal lithotomy position. A speculum is inserted. For LLETZ/RF diathermy, intracervical local anaesthetic (1% lignocaine with 1:100,000 adrenaline) is administered at the 3, 6, 9, and 12 o'clock positions. The selected energy modality is applied under colposcopic or direct vision (total active treatment time: 5–20 minutes depending on technique). Ball diathermy or Monsel's solution is applied for haemostasis if needed. Total time in the procedure room: 20–40 minutes.

• Step 6 — Recovery Room: 1–2 hours of observation. Vital signs, bleeding check. Mild cramping is managed with ibuprofen 400 mg or paracetamol 1 g orally. The vast majority of patients are discharged on the same day.

IMMEDIATE POST-PROCEDURE (Days 1–7):

• Step 7 — Discharge Instructions: Expected vaginal discharge (watery, brownish, or blood-tinged) for 1–4 weeks. Patient is given written instructions to avoid: tampons (use sanitary pads only), sexual intercourse, swimming, strenuous exercise, and intravaginal products for a minimum of 4 weeks. Analgesics prescribed for cramping. Antibiotics (e.g., doxycycline 100 mg BD for 7 days) prescribed if concurrent Chlamydia screen was positive.

• Step 8 — First Follow-up (Day 3–5): In-person or teleconsultation review. Check for signs of secondary infection (offensive discharge, fever >38°C, worsening pain) or delayed haemorrhage. If LLETZ was performed, histology results are reviewed at this visit.

INTERMEDIATE RECOVERY (Weeks 1–4):

• Step 9 — Fit-to-Fly Assessment (Day 7–10): The gynaecologist performs a speculum examination to confirm adequate healing and absence of active bleeding. A fit-to-fly letter is issued. Patients are advised to remain well-hydrated on the flight, wear graduated compression stockings (DVT prophylaxis), and avoid heavy lifting in transit.

• Step 10 — Resumption of Activity: Light work from Day 3–5; desk/office work by Week 1. Avoid sexual intercourse for 4 full weeks (minimum). Light exercise (walking) from Week 1; gym/swimming from Week 4–6.

LONG-TERM FOLLOW-UP (Months 3–12):

• Step 11 — Remote Follow-up (Month 3): Teleconsultation with the GAF Healthcare patient liaison. Symptom review: has discharge, PCB, or discomfort resolved? If yes, standard smear/HPV follow-up per national programme applies.

• Step 12 — Repeat Colposcopy (Month 4–6): Recommended for LLETZ patients; HPV test of cure at 6 months (per NHSCSP/ASCCP protocol). If HPV-negative at 6 months, return to routine 5-yearly screening. If HPV-positive, colposcopy repeated at 12 months.

• Step 13 — Discharge from Active Follow-up: Most patients are discharged from specialist follow-up at 6–12 months with confirmed symptom resolution and negative HPV test of cure.